J Rheum Dis.  2022 Jan;29(1):56-57. 10.4078/jrd.2022.29.1.56.

Colchicine as a Potential Treatment Choice for COVID-19 Patients in Developing Countries: COVID-19 and Colchicine

• Ghang B
• Kim J

• KMID: 2523461
• DOI: http://doi.org/10.4078/jrd.2022.29.1.56

Reference

1. Tang KT, Hsu BC, Chen DY. 2021; Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 12:645013. DOI: 10.3389/fimmu.2021.645013. PMID: 33777042. PMCID: PMC7994612.

2. Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. 2021; Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 299:E177–86. DOI: 10.1148/radiol.2021203153. PMID: 33497317. PMCID: PMC7841877.

3. Ricke DO. 2021; Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front Immunol. 12:640093. DOI: 10.3389/fimmu.2021.640093. PMID: 33717193. PMCID: PMC7943455.

4. Martins-Filho PR, Ferreira LC, Heimfarth L, Araújo AAS, Quintans-Júnior LJ. 2021; Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta- analysis of blinded, placebo-controlled, randomized clinical trials. Lancet Reg Health Am. 2:100062. DOI: 10.1016/j.lana.2021.100062. PMID: 34485970. PMCID: PMC8403035.

5. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. 2020; Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open. 3:e2013136. DOI: 10.1001/jamanetworkopen.2020.13136. PMID: 32579195. PMCID: PMC7315286.

6. Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, et al. 2021; Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 7:e001455. DOI: 10.1136/rmdopen-2020-001455. PMID: 33542047. PMCID: PMC7868202.

7. Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, et al. 2020; Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 79:1286–9. DOI: 10.1136/annrheumdis-2020-217712. PMID: 32732245. PMCID: PMC7509521.

8. Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH, et al. 2021; Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 9:924–32. DOI: 10.1016/S2213-2600(21)00222-8.

9. Chappey O, Scherrmann JM. 1995; [Colchicine: recent data on pharmacokinetics and clinical pharmacology]. Rev Med Interne. 16:782–9. French. DOI: 10.1016/0248-8663(96)80790-9.

10. Hardy RS, Raza K, Cooper MS. 2020; Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 16:133–44. DOI: 10.1038/s41584-020-0371-y. PMID: 32034322.

11. Leung YY, Yao Hui LL, Kraus VB. 2015; Colchicine--update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 45:341–50. DOI: 10.1016/j.semarthrit.2015.06.013. PMID: 26228647. PMCID: PMC4656054.